Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01815736 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,443
- Enrollment target
NCT01815736 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 1,443 participants.
The verdict
NCT01815736, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,443 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically suppressed HIV-infected participants as determined by having HIV-1 RNA \< 50 copies/mL at Week 48.
Interventions
- DRUG ATV
- DRUG E/C/F/TAF
- DRUG RTV
- DRUG E/C/F/TDF
- DRUG EFV/FTC/TDF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,443 participants |
| Start Date | 2013-03-27 |
| Est. Completion | 2020-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01815736
The ClinicalTrials.gov registry entry for NCT01815736 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,443 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ATV is the first listed.
NCT01815736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01815736 about?
NCT01815736 is a clinical study titled "Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants". The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically suppressed HIV-infected participan...
What is the current status of trial NCT01815736?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,443 participants. The study started on 2013-03-27. Estimated completion is 2020-04-01.
What interventions are being tested in trial NCT01815736?
The interventions under investigation include: ATV (DRUG), E/C/F/TAF (DRUG), RTV (DRUG), E/C/F/TDF (DRUG), EFV/FTC/TDF (DRUG).
Who is sponsoring clinical trial NCT01815736?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.